Bioventus Inc. Class A Common Stock (BVS)

FairStock Score: 52/100 — MIXED

Key Financials

Strengths

• Generates $28 million in annual free cash flow (4.3% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Solid return on equity of 13.2% above cost of capital

Concerns

• Trades significantly above Graham Number ($5) with negative 116% margin of safety—limited downside protection
• Altman Z-Score of 0.7 places it in the financial distress zone—elevated bankruptcy risk
• No meaningful dividend despite modest growth—total return depends entirely on multiple expansion

AI Analysis

Bioventus Inc. Class A Common Stock is a micro-cap healthcare company valued at $658 million. The business generates $568 million in annual revenue with a 2.6% net margin and $28 million in free cash flow. From a quality standpoint, Bioventus shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 0.7 warrants caution. On valuation, the stock is trading at a premium 29.4x earnings, with trades far above its Graham Number ($5) with no margin of safety. Growth dynamics show revenue growing at 2.8% and profit growth of 9558.3%. Our composite FairStock Score of 52/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $28 million in annual free cash flow (4.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer